Biotronik launches first US FDA-approved CRM devices with MRI AutoDetect technology

Biotronik Ilivia

Biotronik has announced the availability of the first US Food and Drug Administration (FDA)-approved cardiac rhythm management (CRM) devices with technology that automatically recognises when a patient enters a magnetic resonance imaging (MRI) environment.

The company’s MRI AutoDetect technology is designed to ensure patients with CRM devices can safely undergo MRI scans, while minimising programming burdens for hospitals.

Once activated by a physician, MRI AutoDetect should be able to automatically recognise when the patient enters an MRI environment and convert the device to MRI mode. When the scan is complete, MRI AutoDetect is designed to automatically return the device to its permanent program. Physicians can program MRI AutoDetect to be active for up to 14 days, according to a press release, allowing patients flexibility to undergo, reschedule or repeat MRI scans as needed during the set timeframe.

MRI AutoDetect is currently available on BIOTRONIK’s newest line of CRM devices, including the Ilivia series for tachycardia.